The $90 billion Indian pharma industry has been unable to develop a new drug for the US market despite spending millions in research, even though Indian generics constitutes 40 per cent of US generic drug imports. Ranbaxy and Zydus have been able to launch indigenously developed new drugs in domestic market, but none of the Indian pharmaceutical companies have launched a new drug approved by USFDA. Until a few years ago (2005–2012), Para IV filing opportunities in the US had engaged the Indian firms quiet significantly. Today, that option is no longer is attractive due to limited Para IV opportunities being targeted by numerous firms. Of late, super generics have emerged as the industry’s hope for the future. They have caught the attention of branded players as some categories enjoy a measure of patent protection (3–5 years) in US under Section 505(b)(2) of the Federal Food, Drug and Cosmetic Act (FFDCA). This article is aimed at studying the concept of incremental research in pharmaceutical industry, development cycle and regulatory pathway for super generics, profitability estimates and possibilities in future for Indian firms.
BareiF.PenL.C.SimoensS. (2013). The generic pharmaceutical industry: Moving beyond incremental innovation towards re-innovation. Generics and Biosimilars Initiative Journal, 2(1), 13–19.
2.
BerndtE.R.CockburnI.M.GrépinK.A. (2006). The impact of incremental innovation in biopharmaceuticals: Drug utilization in original and supplemental indications. Pubmed.gov, (Suppl 2), 69–86. doi:10.2165/00019053-200624002-00008
3.
ClaxtonA.J.CramerJ.PierceC. (2011). A systematic review of associations between dose regimens and medication compliance. Pubmed.gov. Retrieved 13October2014, from www.ncbi.nlm.nih.gov/pubmed/11558866
Dr. Reddy’s Laboratories. (n.d.). Annual report2013–14.
6.
GarudS.S.DerleD.V.DerleN.D. (2014). Supergenerics—a cost saving paradigm. International Journal of Pharmaceutical Research and Development, 5(11), 57–66.
GVGFNFYG (2013). Generating value in generics: Finding the next five years of growth. Global Generics Interest Group. McKinsey & Company. Retrived on 21September2014, from www.mckinsey.com/dotcom/pdfs
PadhyB.M.GuptaY.K. (2011). Drug repositioning: Re-investigating existing drugs for therapeutic indications. Journal of Postgraduate Medicine, 57, 153–160. Retrieved on 11August2014, from http://www.jpgmonline.com/text.asp?2011/57/2/153/81870
16.
ParrekA. (2011). A cost effective clinical trial procedures to ensure the smooth development and approval of super generics. 2nd Annual NextGen: Super-generics Strategies. 27–29 April 2011, Mumbai, India. File data.
SommerfeldT. (2005). Strategic options for mid-sized generic players. Journal of Generic Medicines, 2(4), 308–315.
21.
StegemannS.KlebovichI.AntaI.. (2011). Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products. European Journal of Pharmaceutical Sciences, 44(4), 447–454. doi:10.1016/j.ejps.2011.09.012
VernonJ.A.HughenW.K.TrujilloA.J. (2007). Pharmaceutical manufacturing efficiency, drug prices and public health: Examining the causal links. Drug Information Journal, 41(2), 229–239.
26.
YuLX (2008): Pharmaceutical quality by design: product and process development, understanding, and control. Pharm Res. 2008 Apr;25(4): 781–91. Doi: 1007/s11095-007-9511-1. Epub 2008 Jan 10. Retrieved on 20September2014, from www.ncbi.nim.nih.gov/pubmed/18185986
